SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, Ludwig WD, Matutes E, Orfao A, Sperling C, et al.The reliability and specificity of c-KIT for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood1998;92:596599.
  • 2
    Ashman LK, Roberts MM, Gadd SJ, Cooper SJ, Juttner CA.Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. Leuk Res1988;12:923928.
  • 3
    Reuss-Borst MA, Bühring HJ, Schmidt H, Müller CA. AML:Immunophenotypic heterogeneity and prognostic significance of c-KIT expression. Leukemia1994;8:258263.
  • 4
    Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H.Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): Implications for future therapeutical strategies. Eur J Haematol2004;72:89106.
  • 5
    Liu Yin JA, Wheatley K, Rees JK, Burnett AK.Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial. Br J Haematol2001;113:713726.
  • 6
    Stacchini A, Fubini L, Severino A, Sanavio F, Aglietta M, Piacibello W.Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. Leukemia1996;10:15841591.
  • 7
    McKenna HJ, Smith FO, Brasel K, Hirschstein D, Bernstein ID, Williams DE, Lyman SD.Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children. Exp Hematol1996;24:378385.
  • 8
    Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD.Expression and functional role of the proto-oncogene c-KIT in acute myeloblastic leukemia cells. Blood1991;78:29622968.
  • 9
    Wells SJ, Bray RA, Stempora LL, Farhi DC. CD117/CD34 expression in leukemic blasts. Am J Clin Pathol1996;106:192195.
  • 10
    Bradstock K, Matthews J, Benson E, Page F, Bishop J.Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood1994;84:12201225.
  • 11
    Morita S, Tsuchiya S, Fujie H, Itano M, Ohashi Y, Minegishi M, Imaizumi M, Endo M, Takano N, Konno T.Cell surface c-KIT receptors in human leukemia cell lines and pediatric leukemia: Selective preservation of c-KIT expression on megakaryoblastic cell lines during adaptation to in vitro culture. Leukemia1996;10:102105.
  • 12
    Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, Miyawaki S, Kuriyama K, Shimazaki C, Akiyama H, et al.Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004;103:19011908.
  • 13
    Müller-Tidow C, Schwäble J, Steffen B, Tidow N, Brandt B, Becker K, Schulze-Bahr E, Halfter H, Vogt U, Metzger R, et al.High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res2004;10:12411249.
  • 14
    Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, et al.Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood2005;105:5460.
  • 15
    Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W.The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood2003;101:14941504.